NUMIDARGISTAT

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C11H22BN3O5
Molecular Weight	287.12
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](N)C(=O)N1C[C@H](CCCB(O)O)[C@@](N)(C1)C(O)=O

InChI

InChIKey=ZZJLMZYUGLJBSO-LAEOZQHASA-N

InChI=1S/C11H22BN3O5/c1-7(13)9(16)15-5-8(3-2-4-12(19)20)11(14,6-15)10(17)18/h7-8,19-20H,2-6,13-14H2,1H3,(H,17,18)/t7-,8-,11-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C11H22BN3O5
Molecular Weight	287.12
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Arginase-2, mitochondrial 24 Target ID: CHEMBL1795148 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29254508	Inhibitor 8504		296.0 nM [IC50]
Arginase-1 25 Target ID: CHEMBL1075097 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29254508	Inhibitor 8504		86.0 nM [IC50]

C_max

Value	Dose	Analyte	Population
3.3 μM OTHER https://www.calithera.com/wp-content/uploads/2017/12/CB-1158-101-ASCO-2017-FINAL.pdf	50 mg 2 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	NUMIDARGISTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.4 μM OTHER https://www.calithera.com/wp-content/uploads/2017/12/CB-1158-101-ASCO-2017-FINAL.pdf	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	NUMIDARGISTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.9 μM OTHER https://www.calithera.com/wp-content/uploads/2017/12/CB-1158-101-ASCO-2017-FINAL.pdf	150 mg 2 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	NUMIDARGISTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
30.2 μM × h OTHER https://www.calithera.com/wp-content/uploads/2017/12/CB-1158-101-ASCO-2017-FINAL.pdf	50 mg 2 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	NUMIDARGISTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
80.6 μM × h OTHER https://www.calithera.com/wp-content/uploads/2017/12/CB-1158-101-ASCO-2017-FINAL.pdf	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	NUMIDARGISTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
85.5 μM × h OTHER https://www.calithera.com/wp-content/uploads/2017/12/CB-1158-101-ASCO-2017-FINAL.pdf	150 mg 2 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	NUMIDARGISTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
6.2 h OTHER https://www.calithera.com/wp-content/uploads/2017/12/CB-1158-101-ASCO-2017-FINAL.pdf	50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NUMIDARGISTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6 h OTHER https://www.calithera.com/wp-content/uploads/2017/12/CB-1158-101-ASCO-2017-FINAL.pdf	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NUMIDARGISTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5 h OTHER https://www.calithera.com/wp-content/uploads/2017/12/CB-1158-101-ASCO-2017-FINAL.pdf	150 mg 2 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NUMIDARGISTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.	2017-12-19	29254508

Substance Class	Chemical Created by `admin` on `Tue Apr 01 16:46:25 GMT 2025` Edited by `admin` on `Tue Apr 01 16:46:25 GMT 2025`
Record UNII	IFD73D535A
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CB-1158

Preferred Name

English

NUMIDARGISTAT

Official Name

English

numidargistat [INN]

Common Name

English

Numidargistat [WHO-DD]

Common Name

English

3-PYRROLIDINECARBOXYLIC ACID, 3-AMINO-1-((2S)-2-AMINO-1-OXOPROPYL)-4-(3-BORONOPROPYL)-, (3R,4S)-

Systematic Name

English

NUMIDARGISTAT [USAN]

Common Name

English

INCB-001158

Code

English

(3R,4S)-3-AMINO-1-((S)-2-AMINOPROPANOYL)-4-(3-BORONOPROPYL)PYRROLIDINE-3-CARBOXYLIC ACID

Systematic Name

English

INCB001158

Code

English

ARGINASE INHIBITOR INCB001158

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C308